REG - Kanabo Group PLC - Director/PDMR Dealing

KanaboAnnouncement

25/02/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220225:nRSY7843Ca&default-theme=true

RNS Number : 7843C  Kanabo Group PLC  25 February 2022

Kanabo Group Plc

("Kanabo" or the "Company")

 

Director/PDMR Dealing

 

Kanabo Group Plc (LSE:KNB), the pan-European medical cannabis Company
focussing on the development and distribution of cannabis-derived products for
medical patients and wellness CBD consumers, announces Daniel Poulter, Non-
Executive Director, has purchased 55,000 ordinary shares at a price of 7.4p.

 

Avihu Tamir, CEO, commented: "Since joining Kanabo in June 2021 Dan has become
an invaluable member of the board. I welcome his most recent show of support
by acquiring shares in the market. With the recent acquisition of the GP
Service, and completion of an oversubscribed fundraise, Kanabo has
approximately £6.4m and is well positioned to implement its growth strategy".

 

The notification set out below is provided in accordance with the requirements
of Article 19 of the UK Market Abuse Regulation.

 

 

For further information, please visit http://www.kanabogroup.com/ or contact
the following:

 Kanabo Group Plc                            Via Vox Markets
 Avihu Tamir, CEO
 Peterhouse Capital Ltd (Financial Adviser)  Tel: +44 (0)20 7469 0930
 Eran Zucker / Lauren Riley
 Peterhouse Capital Ltd (Corporate Broker)   Tel: +44 (0)20 7469 0930
 Lucy Williams / Charles Goodfellow
 Vox Markets (Investor Relations)            KanaboGroup@voxmarkets.co.uk
 Kat Perez                                   kperez@voxmarkets.co.uk

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name

      Daniel Poulter

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Director

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer, or auction monitor

 a)   Name                                                         Kanabo Group Plc

 b)   LEI                                                          213800XPJFSNWJIYKN52

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 2.5 pence each in Kanabo Group Plc

      Identification code                                          GB00BYQCS703

 b)   Nature of the transaction                                    Purchase of shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     7.4p              55,000

 d)   Aggregated information

      - Aggregated volume                                          55,000

      - Price                                                      £4,053

 e)   Date of the transaction                                      24/02/2022

 f)   Place of the transaction                                     Standard List of the Main Market

 

Following the share purchase, Mr Poulter's beneficial interests in the capital
of the Company is 0.013%.

 

About Kanabo Group Plc

Kanabo Group Plc is creating a new standard in the medical cannabis industry
to improve the well-being of millions of people around the world by providing
a better alternative to the smoking of medicinal cannabis flowers. Kanabo,
which was the first medicinal cannabis company to IPO on London Stock
Exchange, has a focus on the distribution of cannabis-derived products for
medical patients and non-THC products for CBD consumers. It has conducted
extensive Research & Development to produce high-quality cannabis extract
formulas, innovative medical-grade vaporizers, and various non-smoking
consumption solutions. Kanabo sells a range of medical cannabis products and
wellness CBD products in the Primary Markets, including its VapePod, which
delivers a metered dose with every inhalation.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHPPUQPPUPPGBC